Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aditxt Inc ADTX

Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.


NDAQ:ADTX - Post by User

<< Previous
Bullboard Posts
Next >>
Post by whytestockson Sep 24, 2024 6:30pm
40 Views
Post# 36239280

InvestorNewsBreaks - Aditxt (NASDAQ: ADTX) Acquisition Targe

InvestorNewsBreaks - Aditxt (NASDAQ: ADTX) Acquisition Targe
NEWS: $ADTX InvestorNewsBreaks - Aditxt (NASDAQ: ADTX) Acquisition Target Files Preliminary Proxy Seeking Stockholder ApprovalAditxt&#xA0;(NASDAQ: ADTX) , an innovation platform dedicated to accelerating promising health innovations, has reported that its acquisition target, Evofem Biosciences (OTCQB: EVFM) , a women&#x2019;s health company, has filed a&#xA0;preliminary proxy. The proxy is seeking stockholder approval ...ADTX - InvestorNewsBreaks - Aditxt (NASDAQ: ADTX) Acquisition Target Files Preliminary Proxy Seeking Stockholder Approval

<< Previous
Bullboard Posts
Next >>